UNSPSC 51152103: Atropine/hyoscyamine/phenobarbital/scopolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.

UNSPSC 51152103 Atropine/hyoscyamine/phenobarbital/scopolamine is a Commodity code that, based on recent state and local procurement activity, does not map consistently to the pharmaceutical compounds in its title. The Seminole County, Florida opportunity posted in June 2026 sought naloxone and drug deactivation systems—opioid-reversal and pharmaceutical disposal products outside the anticholinergic and sedative scope of the code name. The Texas Health and Human Services Commission's April 2026 Request for Information (RFI) on direct-to-manufacturer prescription programs addresses pharmacy benefit strategy broadly, without specifying therapeutic class. The issuing bodies include county health departments and state health and human services agencies pursuing health-system acquisitions and program innovation, but the code shows little coherent recent activity aligned to its stated pharmaceutical scope.

Activity under this code appears limited and geographically scattered. The Seminole County IFB (IFB60459723LAS) with a July 26, 2023 response deadline represents a standalone procurement for community health support with quarterly deliveries, while the Texas RFI (HHS0017013, response due April 3, 2026) functions as exploratory market intelligence rather than a committed procurement. No other recent opportunities are identified in the source. The mismatch between the code's nominal scope—anticholinergic and sedative pharmaceutical compounds—and the actual solicitations posted suggests either miscoding by issuing bodies or limited utility of this Commodity code for tracking state and local pharmaceutical procurement activity in its intended category.